Colon Cancer - Walking for a future
Walking for a future
Town Online - Sep 29 9:14 AM
My youngest daughter, Jennifer, walked 26.2 miles on Sunday. It took her a little less than eight hours. She walked for her uncle, who died of cancer two years ago. She walked for her grandmother, who died of cancer eight years ago. She walked for her father-in-law, who died of cancer 13 years ago.Save to My Web
Program Helps Spot Colon Cancer Risk Factors
NBC 6 Miami - Sep 26 8:12 PM
A new Web-based program can help families determine if they have a genetic risk and should seek out testing for colon cancer.Save to My Web
Computer Model Predicts Colon Cancer Inheritable Genetic Defects
Science Daily - Sep 28 9:01 AM
A new prediction model for genetic defects known as Lynch syndrome, which predisposes families to develop colorectal cancer, was created by researchers from the Johns Hopkins University and other institutions. The model, called MMRpro, is based on an individual’s detailed family history of colorectal and endometrial cancer, as well as knowledge of how genetic mutations manifest themselves — in Save to My Web
Amgen Prices Colon Cancer Drug 20% Below ImClone Rival
Bio-IT World - Sep 28 8:23 AM
September 28, 2006 | The move by Amgen appeared to be both a competitive strategy and an acknowledgment of recent public concerns about the costs of some of the newest cancer drugs, which run tens of thousands of dollars a year.Save to My Web
FDA Approves Vectibix(TM) to Treat Patients with Metastatic Colorectal Cancer
[Press Release] Business Wire via Yahoo! Finance - Sep 27 1:47 PM
THOUSAND OAKS, Calif.—-Amgen today announced that the U.S. Food and Drug Administration has approved Vectibix following priority review. Vectibix is the first entirely human monoclonal antibody for the treatment of patients with epidermal growth factor receptor- expressing metastatic colorectal cancer after disease progression on, or following fluoropyrimidine-, oxaliplatin-, and irinotecan- Save to My Web